Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix™-B in an Adult Non-Responder Population

NCT00697931 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00697931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00697931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix™-B in an Adult Non-Responder Population
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
May 31, 1997
Completion date
June 30, 1998
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b